• PExA posted Q2 net sales of SEK 82,800, down 73.51% year over year.
• Loss after financial items narrowed to SEK 1.25 million; EPS improved to a loss of SEK 0.01.
• H1 net sales rose to SEK 1.19 million, more than doubled from a year earlier; loss after financial items narrowed to SEK 2.2 million.
• Cash fell to SEK 796,326; equity ratio dropped 14.1 percentage points to 53%.
• Signed a 7.5 MSEK, 18-month deal to supply 10 PExA 2.1 systems for an IPF clinical study; launched a fully underwritten 9.9 MSEK rights issue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PExA AB published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.